BRCA2 and ovarian carcinoma: Given that CDK5RAP3 interacts with BRCA2, whose mutations considerably increase the risk of breast and ovarian cancer, and that CDK5RAP3 downregulation leads to DNA damage resistance, we hypothesized that CDK5RAP3 expression may be associated with poorer survival of breast and ovarian cancer patients.